生命科学资讯

Boehringer axes MASH deal with OSE as biotech continues to whittle down pipeline

BioAtla lays off 70% of workforce, searches for buyers for antibody pipeline

United Therapeutics’ phase 3 win tees up filing to challenge J&J in cardiac condition

UniQure shares crash 40% as FDA rejects early approval path for Huntington's gene therapy

FDA fully releases clinical hold on Intellia CRISPR gene therapy trials

Aardvark pauses phase 3 metabolic drug study over 'cardiac observations,' sinking sock

Roche reports another phase 3 multiple sclerosis win, but deaths add to safety questions

BioNTech advances DualityBio ADC into phase 3 with half the patients of Merck-Daiichi rival

Atrium arises from Novartis' Avidity buy with $270M, pair of preclinical cardio candidates

Lilly debuts Nvidia supercomputer with fanfare and focus on escaping traditional pharma lifecycle

Chutes & Ladders—Sarepta CEO to step down as DM1 hits close to home

FDA slams ExThera with warning letter over controversial blood filter device

Generate scores largest biotech IPO since 2024 with $400M Nasdaq listing

Thermo Fisher unveils test to aid in dosing of antirejection drug

Earendil pens $885M pact to use WuXi XDC's linker tech for next-gen ADCs

Spatial Biomarker Panels for Clinical Trials

As CAR-T cell therapy gains ground on solid tumors, regulatory red tape hinders progress

'Like talking to a brick wall': Senate hearing takes aim at FDA's rare disease review process

Sarepta CEO Doug Ingram to retire after a decade of Duchenne breakthroughs and controversies

Analysts see potential in MDMA drug after AtaiBeckley reports improvements in anxiety trial